Evercore ISI maintains Kenvue stock rating amid Tylenol autism study concerns

Kenvue Inc. (KVUE) shares have seen significant volatility, falling over 10% in the past week, largely due to concerns stemming from a reported Department of Health and Human Services study, led by Robert F. Kennedy Jr., investigating a potential link between prenatal acetaminophen use (Tylenol) and autism risk. While a subsequent Bloomberg report cited HHS describing the connection as "merely speculation," Tylenol represents 15% of Kenvue's U.S. sales and is its largest profit pool. Analyst reactions are mixed: Evercore ISI reiterated an "In Line" rating with a $25 target, while RBC Capital lowered its target to $22.00 citing a "soft" quarter and regulatory scrutiny, and Jefferies reduced its target to $25.00 on a challenging 2025 outlook, though BofA Securities maintained its "Buy" rating, highlighting the ongoing impact of product safety concerns and regulatory scrutiny on investor sentiment.

Analysis

Kenvue Inc. (KVUE) is facing significant stock price pressure and investor uncertainty, with its shares declining 10.09% over the past week. The primary catalyst is a report of an upcoming Department of Health and Human Services study examining a potential link between prenatal acetaminophen use and autism, directly impacting Kenvue's flagship Tylenol brand. This risk is substantial, as Tylenol constitutes approximately 15% of the company's U.S. sales and is its largest profit generator, commanding a 25% price premium over private label competitors. While a subsequent report citing an HHS source described the link as "merely speculation," the market has clearly priced in a significant risk, pushing the stock's RSI into oversold territory. Analyst sentiment is fractured: RBC and Jefferies have lowered price targets to $22 and $25 respectively, citing not only the litigation overhang but also fundamental headwinds like a "soft" quarter and a challenging 2025 outlook. Conversely, BofA Securities and Jefferies itself maintain "Buy" ratings, while Evercore ISI holds an "In Line" rating, indicating a wide divergence in views on whether the company's strong underlying fundamentals, such as its 58.15% gross profit margin, can outweigh the regulatory and legal threats.

Key Decisions for Investors

• Investors should closely monitor all developments regarding the HHS study on acetaminophen, as its outcome represents the most significant near-term catalyst for KVUE and could also impact competitors like Haleon and Perrigo.
• The sharp 10% weekly decline and oversold RSI may present a tactical, contrarian opportunity for risk-tolerant investors who believe the market has overreacted, especially given the subsequent HHS clarification calling the link speculative.
• It is crucial to weigh the company's strong gross profit margins against the dual headwinds of potential litigation risk and analyst concerns over softer revenue growth and margin pressures in 2025.